Can-Fite BioPharma Ltd.CANFNYSE
Loading
EPS Growth TrendStable
Percentile Rank36
Year-over-Year Change
Year-over-year earnings per share growth rate
Latest
0.00%
↑ 100% vs avg
Percentile
P36
Within normal range
Streak
1 qtr
Consecutive declineStable
Average
-59.19%
Historical baseline
| Period | Value |
|---|---|
| Q2 2025 | 0.00% |
| Q1 2025 | 12.50% |
| Q4 2024 | 0.00% |
| Q3 2024 | 27.27% |
| Q2 2024 | 0.00% |
| Q1 2024 | 0.00% |
| Q4 2023 | 21.43% |
| Q3 2023 | 0.00% |
| Q2 2023 | 36.36% |
| Q1 2023 | 40.54% |
| Q4 2022 | -19.35% |
| Q3 2022 | -14.81% |
| Q2 2022 | 10.00% |
| Q1 2022 | 70.30% |
| Q4 2021 | -62.90% |
| Q3 2021 | 0.00% |
| Q2 2021 | -58.97% |
| Q1 2021 | 50.00% |
| Q4 2020 | -39.29% |
| Q3 2020 | 55.56% |
| Q2 2020 | 49.80% |
| Q1 2020 | 31.98% |
| Q4 2019 | -14.60% |
| Q3 2019 | 23.33% |
| Q2 2019 | -5.00% |
| Q1 2019 | 52.89% |
| Q4 2018 | -1874.42% |
| Q3 2018 | 86.26% |
| Q2 2018 | 37.40% |
| Q1 2018 | 32.89% |
| Q4 2017 | -346.11% |
| Q3 2017 | 70.02% |
| Q2 2017 | -34.54% |
| Q1 2017 | 68.15% |
| Q4 2016 | -60.89% |
| Q3 2016 | -63.89% |
| Q2 2016 | 11.65% |
| Q1 2016 | -607.27% |
| Q4 2015 | 107.86% |
| Q3 2015 | -61.85% |